Cocrystal Pharma Confirms Nasdaq Listing Under COCP
Ticker: COCP · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, exchange-listing, corporate-governance
TL;DR
**COCP confirms Nasdaq listing, business as usual.**
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on January 8, 2024, primarily to disclose its registration on The Nasdaq Stock Market LLC under the trading symbol COCP. This filing confirms the company's compliance with exchange listing requirements and provides updated contact information. For investors, this matters because continued listing on Nasdaq ensures liquidity and visibility, which are crucial for stock valuation and investor confidence.
Why It Matters
This filing confirms Cocrystal Pharma's continued listing on a major exchange, which is vital for maintaining investor access and the stock's liquidity.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing confirming existing information, posing minimal new risk.
Analyst Insight
This filing is largely administrative, confirming existing information. Smart investors would note the continued Nasdaq listing as a positive for liquidity but would look for more substantive filings for investment decisions.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where Cocrystal Pharma's stock is registered
- COCP (other) — the trading symbol for Cocrystal Pharma, Inc.
- January 8, 2024 (date) — date of earliest event reported and filing date
FAQ
What is the primary purpose of this 8-K filing by Cocrystal Pharma, Inc.?
The primary purpose of this 8-K filing is to report the date of the earliest event, January 8, 2024, and to disclose information under Regulation FD and Financial Statements and Exhibits, specifically confirming its registration on The Nasdaq Stock Market LLC under the trading symbol COCP.
On which stock exchange is Cocrystal Pharma, Inc. registered?
Cocrystal Pharma, Inc. is registered on The Nasdaq Stock Market LLC, as stated in the 'Name of each exchange on which registered' section of the filing.
What is the trading symbol for Cocrystal Pharma, Inc.?
The trading symbol for Cocrystal Pharma, Inc. is COCP, as indicated in the 'Trading Symbol(s)' section of the filing.
What is the business address and phone number of Cocrystal Pharma, Inc. as listed in this filing?
The business address is 19805 N. Creek Parkway, Bothell, WA 98011, and the business phone number is (877) 262-7123, according to the filing.
Has Cocrystal Pharma, Inc. undergone any name changes in the past, according to this filing?
Yes, the filing lists two former company names: BIOZONE PHARMACEUTICALS, INC. (changed on 20110304) and International Surf Resorts, Inc. (changed on 20070917).
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-08 08:00:35
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 281KB
- ex99-1_002.jpg (GRAPHIC) — 601KB
- ex99-1_003.jpg (GRAPHIC) — 282KB
- ex99-1_004.jpg (GRAPHIC) — 309KB
- ex99-1_005.jpg (GRAPHIC) — 261KB
- ex99-1_006.jpg (GRAPHIC) — 281KB
- ex99-1_007.jpg (GRAPHIC) — 322KB
- ex99-1_008.jpg (GRAPHIC) — 368KB
- ex99-1_009.jpg (GRAPHIC) — 317KB
- ex99-1_010.jpg (GRAPHIC) — 306KB
- ex99-1_011.jpg (GRAPHIC) — 230KB
- ex99-1_012.jpg (GRAPHIC) — 442KB
- ex99-1_013.jpg (GRAPHIC) — 202KB
- ex99-1_014.jpg (GRAPHIC) — 364KB
- ex99-1_015.jpg (GRAPHIC) — 272KB
- ex99-1_016.jpg (GRAPHIC) — 280KB
- ex99-1_017.jpg (GRAPHIC) — 318KB
- ex99-1_018.jpg (GRAPHIC) — 329KB
- ex99-1_019.jpg (GRAPHIC) — 343KB
- ex99-1_020.jpg (GRAPHIC) — 217KB
- ex99-1_021.jpg (GRAPHIC) — 213KB
- ex99-1_022.jpg (GRAPHIC) — 309KB
- 0001493152-24-001662.txt ( ) — 9652KB
- cocp-20240108.xsd (EX-101.SCH) — 3KB
- cocp-20240108_lab.xml (EX-101.LAB) — 33KB
- cocp-20240108_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer